methotrexate IV / Generic mfg. - LARVOL DELTA

Unusual Ampullary Presentation of Pediatric Burkitt Lymphoma: Case Report and Literature Review. (PubMed, Clin Med Insights Case Rep) - "Given persistent cholestasis and bleeding risk, the patient underwent Roux-en-Y choledochojejunostomy for biliary decompression, followed by initiation of rituximab-cyclophosphamide-vincristine-doxorubicin-high-dose methotrexate/rituximab-ifosfamide-etoposide-high-dose cytarabine (R-CODOX-M/R-IVAC) with central nervous system prophylaxis...Ampullary BL should be considered in pediatric patients with obstructive jaundice and upper gastrointestinal bleeding. Surgical biliary decompression can stabilize cholestasis and facilitate timely multi-agent chemotherapy."

Journal • B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Cholestasis • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hepatology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Pediatrics • CD20 • MME • MYC

Bedside treatment algorithm for safe administration of 24-hour high-dose methotrexate in adult acute lymphoblastic leukemia. (PubMed, Haematologica) - "Not available."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia

Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial. (PubMed, Blood Cancer J) - P2 | "Among them, 8 had CSF ctDNA clearance while 6 were positive. Overall, Pen-RMA regimen demonstrated encouraging antitumor activity with a manageable toxicity in PCNSL."

Journal • P2 data • CNS Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Thrombocytopenia • Transplantation

INTRAVASCULAR LARGE B-CELL LYMPHOMA DIAGNOSED BY RENAL BIOPSY PRESENTING WITH NEPHROTIC SYNDROME (ISN-WCN 2026) - "His past history included hypertension, dyslipidemia, and chronic obstructive pulmonary disease, treated with amlodipine, atorvastatin, indacaterol, and silodosin...R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) was initiated, followed by high-dose methotrexate for CNS prophylaxis...This case emphasizes the importance of considering hematologic malignancy in the differential diagnosis of nephrotic syndrome with unexplained fever, even in the absence of hematologic abnormalities. Early renal biopsy allowed timely R-CHOP chemotherapy and resulted in favorable clinical and renal outcomes."

Biopsy • B Cell Lymphoma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Diffuse Large B Cell Lymphoma • Dyslipidemia • Glomerulonephritis • Hematological Malignancies • Hypertension • Immunology • Large B Cell Lymphoma • Lymphoma • Metabolic Disorders • Nephrology • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Renal Cell Carcinoma • Renal Disease • Respiratory Diseases • BCL6 • CD20 • IL2 • IRF4 • PTPRC

CLINICAL OUTCOMES AND RENAL RECOVERY AFTER GLUCARPIDASE RESCUE IN HIGH-DOSE METHOTREXATE–INDUCED ACUTE KIDNEY INJURY: A SYSTEMATIC REVIEW (ISN-WCN 2026) - "Its early use supports renal recovery, minimizes systemic toxicity, and allows safe continuation of chemotherapy. Further prospective studies are warranted to optimize timing, patient selection, and integration with renal replacement therapy in MTX-associated nephrotoxicity."

Clinical • Clinical data • Review • Acute Kidney Injury • Brain Cancer • Germ Cell Tumors • Hematological Malignancies • Leukemia • Lymphoma • Nephrology • Osteosarcoma • Renal Disease • Sarcoma • Solid Tumor

CLINICAL OUTCOMES AND RENAL RECOVERY AFTER GLUCARPIDASE RESCUE IN HIGH-DOSE METHOTREXATE–INDUCED ACUTE KIDNEY INJURY: A SYSTEMATIC REVIEW (ISN-WCN 2026) - "Its early use supports renal recovery, minimizes systemic toxicity, and allows safe continuation of chemotherapy. Further prospective studies are warranted to optimize timing, patient selection, and integration with renal replacement therapy in MTX-associated nephrotoxicity."

Clinical • Clinical data • Review • Acute Kidney Injury • Brain Cancer • Germ Cell Tumors • Hematological Malignancies • Leukemia • Lymphoma • Nephrology • Osteosarcoma • Renal Disease • Sarcoma • Solid Tumor

Successful Use of Epcoritamab in Refractory Diffuse Large B-Cell Lymphoma with Central Nervous System Involvement: A Case Report. (PubMed, Case Rep Oncol) - "However, epcoritamab induced a rapid systemic response along with partial neurological improvement. This case highlights the potential role of bispecific antibody therapy in refractory DLBCL with CNS involvement, an area of significant unmet clinical need."

Journal • B Cell Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Three-Hour Infusion of Methotrexate at 3 g/m2 With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS Risk. (PubMed, Am J Hematol) - P | "We evaluated a pharmacokinetic-informed, CNS-directed HD-MTX protocol (3 g/m2 over 3 h, preceded by a bolus) in 336 LBCL patients achieving CMR after RCHOP or derivatives...In conclusion, HD-MTX, administered via a pharmacokinetic-informed, CNS-directed schedule, with or without intrathecal chemotherapy, significantly reduces CNS relapses and improves outcomes in high-risk LBCL patients in CMR. Trial Registration: ClinicalTrials.gov Identifier: NCT07181785."

Journal • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Secondary Central Nervous System Lymphoma

IELSG32: Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (clinicaltrials.gov) - P2 | N=227 | Completed | Sponsor: International Extranodal Lymphoma Study Group (IELSG) | N=126 ➔ 227

Enrollment change • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Transplantation

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL) (ASH 2025) - P1/2 | "Background : With standard high-dose methotrexate (HDMTX) and cytarabine (HDAraC)-basedinductions, half of the patients achieved complete response (CR)...Responders received two cycles of HDAraCfollowed by HD thiotepa-busulfan and ASCT... Both arms met the predetermined threshold of efficacy with 86% and 82% of CR/CRurates in the lenalidomide and ibrutinib arm, respectively. R-MPV plus a BTK-inhibitor or animmunomodulatory drug constitutes an interesting first-line induction for PCNSL patients up to 65 years.Correlation of patient, disease and lymphoid subpopulations characteristics with response in eachtreatment arm will be explored to guide the choice of the targeted therapy. Ancillary studies regardingthe prognostic impact of baseline and end of induction levels of cytokines in the CSF, ctDNA inplasma/CSF and radiomic features, as biomarkers of response, are planned."

Clinical • IO biomarker • P2 data • CNS Disorders • CNS Lymphoma • Hematological Malignancies • Hepatology • Lymphoma • Mental Retardation • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Steven-Johnson Syndrome • CD4 • ICOS • PD-1

Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Children's Cancer Group, China | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov) - P2 | N=16 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Jan 2027 ➔ Jul 2027

Trial completion date • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR

OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma (clinicaltrials.gov) - P3 | N=331 | Active, not recruiting | Sponsor: Klinikum Stuttgart | Recruiting ➔ Active, not recruiting | Trial primary completion date: Feb 2028 ➔ Jun 2028

Enrollment closed • Trial primary completion date • B Cell Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Primary central nervous system lymphoma: Evolving treatment strategies to achieve improved long-term disease control. (PubMed, J Oncol Pharm Pract) - "We discuss modern induction strategies centered on high-dose methotrexate (HD-MTX) and rituximab, consolidation approaches including reduced-dose whole-brain radiotherapy (WBRT), autologous stem cell transplantation (ASCT), and maintenance strategies, as well as emerging therapies for relapsed or refractory disease...Clinical trials of newer agents, alone or added to a backbone of traditional chemotherapy, are warranted in the 1st and subsequent lines of therapy. Continued prospective research and international collaboration are essential to integrate precision oncology to the bedside of patients with PCNSL."

Journal • Review • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Transplantation

High-Dose Methotrexate-Induced Neurotoxicity in a Patient With CNS Lymphoma (SCCM 2026) - "Treatment has now evolved to initiating with high-dose methotrexate (HD-MTX) based combination regimen with rituximab...Following completion of chemotherapy, his peak serum methotrexate level was 17 µmol/L which was decreasing gradually with appropriate leucovorin rescue and supportive hydration...Additionally, there may be a genetic component which is associated with neurotoxicity. This case highlights the importance of understanding rare side effects of HD-MTX and understanding prompt management."

Clinical • Acute Lymphocytic Leukemia • CNS Disorders • CNS Lymphoma • Epilepsy • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pneumonia • Primary Central Nervous System Lymphoma • Renal Disease

Stereotactic radiosurgery for central nervous system lymphoma: a systematic review and meta-analysis. (PubMed, Acta Neurol Belg) - "SRS is associated with promising clinical and radiologic outcomes and low ARE rates in patients with CNSL, serving as a complementary or salvage option."

Journal • Retrospective data • Review • CNS Disorders • CNS Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Oncology

Effect of high-dose methotrexate infusion duration on 48-hour drug levels and toxicity in children with acute lymphoblastic leukaemia: a quality-of-care study. (PubMed, Cancer Chemother Pharmacol) - "Deviations in infusion duration were high and independently drive pharmacokinetic variability and toxicity. Ensuring timely drug delivery is as critical as dose precision."

Journal • Observational data • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia

HAPLOIDENTICAL SCT INDUCES LONG-TERM REMISSION IN PATIENTS WITH BPDCN (EBMT 2026) - "GvHD prophylaxis comprised cyclosporine A, MMF and short-term MTX, plus ATG (2.5mg/kg, days -5 to -2)... HID-SCT was feasible and with low TRM resulting in excellent survival in BPDCN patients, even in no-remission patients. No one relapsed in this cohort, and this demonstrated the stronger GVT effect and long-term diseased control of HID-SCT in BPDCN patients."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia

IMPACT OF PRE-TRANSPLANT CNS-DIRECTED CONSOLIDATION ON POST-TRANSPLANT CNS RELAPSE IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (EBMT 2026) - "Standard triple IT prophylaxis (Dexamethasone/Methotrexate/Ara-C) was utilized... Post-transplant CNS relapse is infrequent but associated with poor outcomes. Intensified pre-transplant CNS-directed consolidation using HD-MTX or extended IT prophylaxis does not reduce the risk of CNS relapse or improve survival in patients with B-ALL undergoing HSCT. However, TBI-based conditioning provides significant protection against CNS recurrence."

Post-transplantation • Pre-transplantation • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Central Nervous System Leukemia • Infectious Disease • Mucositis • Renal Disease • Transplantation

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH CAR-T CELL THERAPY SIGNIFICANTLY IMPROVES PROGRESSION-FREE SURVIVAL IN RELAPSED REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA (EBMT 2026) - "Effective bridging therapy can significantly improve the efficacy of CART in the treatment of R/R CNSL. After bridging therapy is effective, the treatment model of ASCT combined with CAR-T can significantly improve Progression-free survival."

CAR T-Cell Therapy • B Cell Lymphoma • Bone Marrow Transplantation • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Transplantation

IMPACT OF PRE-TRANSPLANT CNS-DIRECTED CONSOLIDATION ON POST-TRANSPLANT CNS RELAPSE IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (EBMT 2026) - "Standard triple IT prophylaxis (Dexamethasone/Methotrexate/Ara-C) was utilized... Post-transplant CNS relapse is infrequent but associated with poor outcomes. Intensified pre-transplant CNS-directed consolidation using HD-MTX or extended IT prophylaxis does not reduce the risk of CNS relapse or improve survival in patients with B-ALL undergoing HSCT. However, TBI-based conditioning provides significant protection against CNS recurrence."

Post-transplantation • Pre-transplantation • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Central Nervous System Leukemia • Infectious Disease • Mucositis • Renal Disease • Transplantation

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PRIMARY CNS LYMPHOMA: A SINGLE-CENTER EXPERIENCE OVER 10 YEARS (EBMT 2026) - "In this single-center experience, autologous HSCT was feasible in selected patients with PCNSL treated with a multimodal approach including radiotherapy. However, long-term survival remained limited, highlighting the aggressive nature of PCNSL and the need for improved consolidation strategies."

Clinical • Acute Myelogenous Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Transplantation

HAPLOIDENTICAL SCT INDUCES LONG-TERM REMISSION IN PATIENTS WITH BPDCN (EBMT 2026) - "GvHD prophylaxis comprised cyclosporine A, MMF and short-term MTX, plus ATG (2.5mg/kg, days -5 to -2)... HID-SCT was feasible and with low TRM resulting in excellent survival in BPDCN patients, even in no-remission patients. No one relapsed in this cohort, and this demonstrated the stronger GVT effect and long-term diseased control of HID-SCT in BPDCN patients."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia

Role of cystatin C in predicting the risk of hypermethotrexemia and kidney injury after high-dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia. (PubMed, Ann Hematol) - No abstract available

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Renal Disease • CST3

Prognostic factors and outcomes of primary CNS lymphoma treated with high-dose methotrexate-based chemotherapy: A 12-year experience from North India (Sarcoma-RC 2026) - "Legal entity responsible for the study Punam Rabha. Funding Has not received any funding."

Biomarker • Brain Cancer • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Solid Tumor